Download PDF
Thromb Haemost 1985; 53(03): 332-336
DOI: 10.1055/s-0038-1661309
Original Article
Schattauer GmbH Stuttgart

The Effect of Ticlopidine on Platelet Functions in Acute Myocardial Infarction

A Double Blind Controlled Trial
J Bjerre Knudsen
1   The Coagulation Laboratory, the Municipal Hospital, Copenhagen, Denmark
,
E Kjøller
2   The Medical Department II, the Municipal Hospital, Copenhagen, Denmark
,
K Skagen
2   The Medical Department II, the Municipal Hospital, Copenhagen, Denmark
,
J Gormsen
1   The Coagulation Laboratory, the Municipal Hospital, Copenhagen, Denmark
› Author Affiliations
Further Information

Publication History

Received 27 February 1984

Accepted 28 February 1985

Publication Date:
18 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A group of 43 consecutive patients with AMI were randomized to treatment with a novel platelet inhibitor, ticlopidine, or placebo in a double blind study. Treatment was started within 12 hr after onset of precordial pain. Patients who had taken drugs with known platelet inhibitory effect prior to the onset of therapy were excluded.

Platelet survival time (PS) was measured 24–36 hr after onset of precordial pain and after 3 months of treatment in both groups. In the early phase of AMI CK-MB and ASAT were taken twice daily for estimation of infarction size. Platelet function, coagulation factors and fibrinolysis parameters were followed sequentially for 21 days and repeated after 3 months.

In the placebo group a significant reduction in PS (5.62 ± 1.63 S. D. days) was measured in the acute phase of AMI compared to PS 3 months after infarction (8.03 ± 1.20 S.D. days). In the ticlopidine group PS was normal during the acute phase (8.35 ± 1.82 S.D. days). After 3 months of treatment PS was normal in both groups. During the first two weeks after AMI significant changes in coagulation parameters and fibrinolysis indicated an increased risk of thrombosis in both groups. These parameters were unaffected by the platelet inhibitory therapy. Estimated by peak CK-MB and ASAT, infarction size was significantly reduced in the ticlopidine group.

Keywords

Platelet survival - Ticlopidine - Acute myocardial infarction
 

  • References

  • 1 Sorkin RP, Tokarsky MJ, Huber-Smith MJ, Steiger JF, MacCann DS. In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction. Am Heart J 1982; 104: 1255-1261
    CrossrefPubMedGoogle Scholar
  • 2 Zahavi J, Dreyfuss F. An abnormal pattern of adenosine diphosphate induced platelet aggregation in acute myocardial infarction. Thrombos Diathes Haemorrh 1969; 21: 76-88
    PubMedGoogle Scholar
  • 3 Packham MA. Methods for detection of hypersensitive platelets. Thromb Haemostas 1978; 40: 175-195
    PubMedGoogle Scholar
  • 4 Knudsen JB, Gormsen J, Skagen K, Amtorp O. Changes in platelet functions, coagulation and fibrinolysis in uncomplicated cases of acute myocardial infarction. Thromb Haemostas 1980; 42: 1513-1522
    PubMedGoogle Scholar
  • 5 Salem HH, Koutts J, Firkin BG. Circulating platelet aggregates in ischaemic heart disease and their correlation to platelet life span. Thromb Res 1980; 17: 707-711
    CrossrefPubMedGoogle Scholar
  • 6 Sobel M. Circulating platelet products in unstable angina pectoris. Circulation 1981; 61: 300-306
    PubMedGoogle Scholar
  • 7 Chesebro JH, Fuster V, Byrne J. Improvement of shortened platelet survival half-life from the early to the late phase of myocardial infarction. Thromb Haemostas 1981; 46: 143
    PubMedGoogle Scholar
  • 8 Maseri A, L’Abale A, Baroldi G, Chierchia S, Marzilli M, Ballestra AM, Severi S, Parodi O, Biagni A, Distante A, Pesola A. Coronary vasospasm as a possible cause of myocardial infarction. N Engl J Med 1978; 299: 1271-1277
    CrossrefPubMedGoogle Scholar
  • 9 Haerem JW. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atherosclerosis 1972; 15: 199-213
    CrossrefPubMedGoogle Scholar
  • 10 Hoffman JI E, Buckberg GD. Pathophysiology of subendocardial ischaemia. Br Med J 1975; 1: 76-79
    CrossrefPubMedGoogle Scholar
  • 11 Dunn F, Soria C, Soria J, Thomaides A, Lee H, Tobelem G, Caen JP. Effet de l’administration de ticlopidine sur la fixation du fibrinogène au niveau des plaquettes. Nouv Revue Fr Hematol 1983; 25: 132-133
    PubMedGoogle Scholar
  • 12 Ashida S, Abiko Y. Effect of ticlopidine and acetylsalicylic acid on generation of prostaglandin I2-like substance in rat arterial tissue. Thromb Res 1978; 13: 901-908
    CrossrefPubMedGoogle Scholar
  • 13 Cattaneo M, Kinlough-Rathbone RL, Winocour PD, Packham MA, Mustard JF. Ticlopidine prolongs shortened platelet survival by inhibiting clearance of altered platelets. Fed Proc 1982; 41: 701
    PubMedGoogle Scholar
  • 14 Wilkinson AR, Hawker RJ, Hawker LM. The influence of antiplatelet drugs on platelet survival after aortic damage or implantation of a dacron arterial prothesis. Thromb Res 1979; 15: 181-189
    CrossrefPubMedGoogle Scholar
  • 15 Panak E, Maffrand JP, Picard-Fraire C, Vallée E, Blanchard J, Ronucci R. Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1983; 13 suppl (Suppl. 01) 1-54
    PubMedGoogle Scholar
  • 16 Gensini GF, Favilla S, Breschi C, Abbate R, Costanzo G, Serneri GG N. Ticlopidine activity on platelet function in patients with enchanged platelet aggregation. A short-term crossover study Haemostasis 1983; 13: 294-300
    PubMedGoogle Scholar
  • 17 Fox KM, Jonathan A, Selwyn A. Effects of platelet inhibition on myocardial ischaemia. Lancet 1982; 2: 727-730
    PubMedGoogle Scholar
  • 18 WHO: Ischaemic Heart Disease Register. Copenhagen: Euro 1970. 51 4
  • 19 Thakur ML, Welch MJ, Joist JH, Coleman RE. Indium-111 labelled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res 1976; 9: 345-357
    CrossrefPubMedGoogle Scholar
  • 20 ICSH Panel on diagnostic application of radioisotopes in haematology. Recommended methods for radioisotope platelet survival studies. Blood 1977; 50: 1137-1144
    PubMedGoogle Scholar
  • 21 Lou HC, Nielsen JD, Bomholt A, Gormsen J. Platelet hyperaggrega- bility in young patients with completed stroke. Acta Neurol Scandinav 1977; 56: 326-334
    PubMedGoogle Scholar
  • 22 Andersen LA, Gormsen J. Platelet aggregation and fibrinolytic activity in transient cerebral ischaemia. Acta Neurol Scand 1976; 55: 76-82
    PubMedGoogle Scholar
  • 23 Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Wille- brand’s disease. J Clin Invest 1971; 50: 244-254
    CrossrefPubMedGoogle Scholar
  • 24 Scandinavian Standardizations of Enzyme Determination. Scand J Clin Lab Invest 1974; 33: 287-295
    CrossrefPubMedGoogle Scholar
  • 25 Gerhardt W, Waldenstrom J. Creatinekinase B-subunit activity in serum after immunoinhibition of M-subunit activity. Clin Chem 1979; 25: 1274-1282
    PubMedGoogle Scholar
  • 26 Folts JD, Crowell Jr EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370
    CrossrefPubMedGoogle Scholar
  • 27 Vik-Mo H. Effects of acute myocardial ischaemia on platelet aggregation in the coronary sinus and aorta in dogs. Scand J Haematol 1977; 19: 68-74
    PubMedGoogle Scholar
  • 28 Vik-Mo H. Platelet accumulation in the myocardium during acute nonthrombotic coronary artery occlusion in dogs. Scand J Haematol 1978; 21: 225-232
    PubMedGoogle Scholar
  • 29 Ruf W, McNamara JJ, Suehiro A, Suehiro G. Platelet trapping in myocardial infarcts in baboons: Therapeutic effect of aspirin. Am J Cardiol 1980; 46: 405-412
    CrossrefPubMedGoogle Scholar
  • 30 Installé E, Gonzalez M, Schoevaerdts JC, Trémouroux J. Prevention by ticlopidine of platelet consumption during extracorporeal circulation for heart surgery and lack of effect on operative and postoperative bleeding. J Cardiovasc Pharmacol 1981; 3: 1174-1183
    CrossrefPubMedGoogle Scholar
  • 31 Maeda K, Usuda M, Kawaguchi S, Shinzato T, Saito A, Ohta K, Kobayashi K, Ohbayashi S. Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys. Artif Organs 1980; 4: 30-33
    CrossrefPubMedGoogle Scholar
  • 32 Ogawa S, Naruse T. Effects of various antiplatelet drugs and defibrinating agent on experimental glomerulonephritis in rats. J Lab Clin Med 1982; 99: 428-441
    PubMedGoogle Scholar
  • 33 Abrahamsen AF. Platelet survival studies in man. Scand J Haematol 1968; 5 suppl (Suppl. 03) 1-86
    PubMedGoogle Scholar
  • 34 Kaplan EJ, Saba TM. Platelet removal from the circulation by the liver and spleen. Am J Physiol 1978; 235: 314-320
    PubMedGoogle Scholar
  • 35 Mustard JF. Platelet survival. Thromb Haemostas 1978; 40: 154-162
    PubMedGoogle Scholar